|
목적 : To evaluate the three-month natural course of recurrent macular edema secondary to branch retinal vein occlusion (BRVO) previously treated with intravitreal bevacizumab.
방법 : This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrent macular edema was not treated (untreated group) or treated with a single intravitreal bevacizumab (treated group). Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were compared at the time of recurrence and three months later.
결과 : At time of recurrence, mean CFT and BCVA were 484.9 ± 124.1 µm and 0.58 ± 0.26, respectively, in untreated group (n = 19). values were 456.3 ± 126.8 µm and 0.51 ± 0.21, respectively, in treated group (n = 17). 3 months later, mean CFT and BCVA had changed to 493.7 ± 123.9 µm and 0.62 ± 0.29, respectively, in untreated group. values were 294.7 ± 104.4 µm and 0.40 ± 0.24, respectively, in treated group. Differences in CFT and BCVA between were not significant in untreated group (P = 0.106 and P = 0.687, respectively), whereas the significant differences were noted in treated group
결론 : Unlike the first episode of macular edema following BRVO, recurrent macular edema following intravitreal bevacizumab therapy did not spontaneously resolve suggesting the need for prompt treatment.
|